LibraryBy pinki shah / May 14, 2022 Speciality — Amyotrophic Lateral Sclerosis (ALS) Biomarkers Biosimilars Bladder Blood Bone Brain Breast Cancer Central Nervous System (CNS) Clinical Trials Colon Colorectal Diversity, Equity & Inclusion Featured Content Gastrointestinal Genitourinary Genomic Geriatric Gynecology Head and Neck Hematologic Hematologic Maglinencies Hematology Immunotherapy Interventional Radiology Kidney Leukemia Liquid Biopsy Liver Lung Lymphoma Malignencies Melanoma Myelodysplastic Syndrome Myeloma Neuroendocrine Novel Oral & Maxillofacial Surgery Ovarian Pancreas Pancreatic Pharmacological Prostate Radiation Radiology Renal Sarcoma Skin Solid Tumor Supportive & Palliative Care Survivorship Telemedicine Thoracic Thrombosis Thymic Thyroid Urothelial Author / Speaker Title of Presentation Type of Media — Video Document Audio Event 2024 Event — 2025 MaTOS Breast 2025 MaTOS GU 2025 PRIMO 2025 South Florida GI Cancer Symposium 2025 Winter Cancer Symposium (WCS) 2024 Advances in Oncology Conference 2024 Best of WCLC San Francisco 2024 California Cancer Consortium Conference (CCC) 2024 MaTOS Lungs 2024 MLS Cleveland 2024 MLS Irvine 2024 MLS Nashville 2024 MLS New Orleans 2024 MLS Seattle 2024 New Orleans Summer Cancer Meeting (NOSCM) 2024 PACC Miami 2024 PRIMO 2024 SPS Puerto Rico 2024 SPS Seattle 2024 SPECTRUM 2024 Sylvester APP Oncology Symposium 2024 Updates in Cancer Therapies 2024 WCS Clear Displaying 1,876 - 1,900 of 2,995 « 1 … 74 75 76 77 78 … 120 » EGFR: Common and Uncommon Mutations - What Is Next for These Patient Populations? By: Joshua Bauml, MD View PDF Masters Debate on Lung Cancer-After Neoadjuvant Therapy for Early-Stage NSCLC, if Surgical Pathology Showed pCR- Would You Offer Adjuvant Therapy? (Part 2) By: Joshua Reuss,MD View PDF Best Approaches for First Line EGFR Mutant NSCLC By: Joshua Sabari, MD View PDF Best Approaches for First Line EGFR Mutant NSCLC By: Joshua Sabari, MD View Video ALK & ROS-1: First Line & Mechanism of Resistance By: Julia Rotow, MD View PDF Mechanism of Resistance to EGFR-ALK & Other Relevant Pathways By: Julia Rotow, MD View Video Mechanism of Resistance to EGFR-ALK & Other Relevant Pathways By: Julia Rotow, MD View PDF ALK & ROS-1: First Line & Mechanism of Resistance By: Julia Rotow, MD View Video ADC in NSCLC: CEACAM5 and Teliso-V By: Julia Rotow, MD View PDF ADC in NSCLC: CEACAM5 and Teliso-V By: Julia Rotow, MD View Video ROS-1 & B-Raf Inhibitors: New Developments By: Julia Rotow, MD View PDF ROS-1 & B-Raf Inhibitors: New Developments By: Julia Rotow, MD View Video K-RAS Therapies in NSCLC By: Julia Rotow, MD View PDF K-RAS Therapies in NSCLC By: Julia Rotow, MD View Video Advances in Small Cell Lung Cancer and Mesothelioma/Thymic Malignancies By: Jyoti Malhotra, MD, MPH View PDF Advances in Small Cell Lung Cancer and Mesothelioma/Thymic Malignancies By: Jyoti Malhotra, MD, MPH View Video Advances in Limited and Extensive Stage Small Cell Lung Cancer By: Jyoti Malhotra, MD, MPH View PDF Advances in Limited and Extensive Stage Small Cell Lung Cancer By: Jyoti Malhotra, MD, MPH View Video The Era of Antibody-Drug Conjugates (ADCs) and Bi-Specifics By: Jyoti Patel, MD View PDF New Developments in Lung Cancer Therapeutics By: Karen Kelley, MD View Video Locally Advanced Non-Small Cell Lung Cancer By: Karen Kelly - MD View Video How I Treat Stage IV Lung Adenocarcinoma without a Driver Mutation and Negative PD-L1 expression By: Karen Kelly (UCD) View PDF Challenging Cases in Oncology By: Karen Kelly (UCD), Aaron Rosenberg (UCD) View Video New Developments in Lung Cancer Therapeutics By: Karen Kelly, MD View PDF Locally Advanced Non-Small Cell Lung Cancer By: Karen Kelly, MD View PDF
